Patients carrying at least one copy of the *3 allele may have decreased clearance of fesoterodine as compared to patients with the *1/*1 genotype. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.